Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CENTRE OSCAR LAMBRET

Home Clinical Trial Sponsors and OrganizationsCENTRE OSCAR LAMBRET

CENTRE OSCAR LAMBRET

ACTIVE

3 RUE FREDERIC COMBEMALE, Lille, Hauts De France, Francewww.centreoscarlambret.frPrivate251–500 employeesEstablished: 1995-01-01

Also known as:

laboratoire

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

157

33 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1995

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

51

32.5%

Phase 2

39

24.8%

Phase 1

20

12.7%

Phase 3

10

6.4%

Phase 4

2

1.3%

Phase 1/2

1

0.6%

Trial Status Distribution

Active, not recruiting

30

19.1%

Completed

70

44.6%

Not yet recruiting

3

1.9%

Recruiting

18

11.5%

Terminated

28

17.8%

Unknown

6

3.8%

Withdrawn

2

1.3%

Clinical Trials

Trials sponsored by this organization (157)

Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a Pediatric Oncology Department

Sep 202720 participants

Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

Not yet recruiting

Mar 20271,100 participants

Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome

Oct 2026123 participants

Benefits of Early Collaboration Between Oncologists and Palliative Care Physicians in Cases of Unplanned Hospitalization for Patients With Metastatic Cancer

Not yet recruiting

Oct 2026493 participants

Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy on Ultra-central Lung Tumors on MR-Linac

Not yet recruiting

Sep 202659 participants

Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall

Jul 2026135 participants

Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma

Jun 2025371 participants

Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients

Jun 202575 participants

Page 1 of 20

Approvals

No approval data available

News

Capivasertib Shows Significant Survival Benefit in PTEN-Deficient Metastatic Prostate Cancer

- The CAPItello-281 phase 3 trial demonstrated that adding capivasertib to standard therapy prolonged radiographic progression-free survival by 7.5 months in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. - The combination achieved a median rPFS of 33.2 months compared to 25.7 months with placebo, representing a statistically significant 19% reduction in disease progression risk. - Greater PTEN deficiency correlated with increased treatment benefit, with patients showing 100% PTEN loss experiencing the most pronounced survival improvements. - The safety profile showed manageable toxicities, with diarrhea, hyperglycemia, and rash being the most common adverse events in the capivasertib arm.

On this page

Overview
Clinical Trials157
Approvals
News1

Back to Organizations